A decent end to FY24: investors jittery with biopharma headwinds
31/01/25 -"During FY24, Eurofins’ revenue was in line with market expectations, but the EPS and FCF outperformed. The initial knee-jerk reaction was attributable to continued weakness in the Biopharma ..."
Pages
47
Language
English
Published on
31/01/25
You may also be interested by these reports :
17/07/26
DKSH’s H1 ‘26 results were a mixed bag, with sales and EPS ahead of market expectations, but Core EBIT was below consensus due to Consumer Goods ...
16/07/26
Experian delivered an in-line Q1 FY26/27, with 7% organic revenue growth supported by resilient B2B demand, while temporary data breach contract ...
17/06/26
The 2030 strategy confirms the group’s long-term trajectory. It focuses on a continuing move to high-value services, supported by technology, risk ...
04/06/26
Following Bilfinger’s Q1 results, we have revised our estimates to the midpoint of management guidance, which we consider a fair reflection of the ...